Articles
Latest Articles
Evidence-based analysis and clinical commentary on peptide therapeutics — updated as the literature evolves. · 19 articles
Does Catestatin Peptide Reduce Tau, Amyloid, and Neuroinflammation in Preclinical Alzheimer's Disease Models in 2026?
In preclinical models studied through 2026, catestatin (CST) — a 21-amino-acid peptide derived from chromogranin A — reduces tau hyperphosphorylation and aggregation, lowers amyloid plaque burden, suppresses glial neuroinflammation, and restores both cognitive and motor function. All evidence is from rodent models; no human clinical trials have been initiated as of 2026.
How Does Semaglutide's GLP-1R/SIRT1 Axis Address Brain Insulin Resistance as a Metabolic Root of Cognitive Decline in 2026?
The 2026 Alhowail review in Frontiers in Aging Neuroscience frames brain insulin resistance — not amyloid burden alone — as the upstream metabolic lesion that semaglutide's GLP-1R/SIRT1/GLUT4 axis is best positioned to correct. Preclinical data show restored cerebral glucose uptake, suppressed NLRP3 inflammasome activation, and attenuated tau hyperphosphorylation, but human prevention trials in at-risk populations remain the critical missing evidence.
What Safety Signals Has MK-677 (Ibutamoren) Produced in Human Trials, and How Serious Is the Congestive Heart Failure Risk in 2026?
Ibutamoren mesylate has produced clinically significant safety signals in human trials. The most serious is congestive heart failure and a trial was terminated early after CHF occurred in six-point-five percent of treated elderly patients versus one-point-six percent on placebo. Ibutamoren carries no FDA approval as of 2026.
Does CRB-913's Peripherally Restricted CB1 Inverse Agonism Offer a Clinically Meaningful Non-Incretin Obesity Mechanism in 2026?
Yes, with important caveats. CRB-913's 2026 CANYON-1 Phase 1b readout showed 5% placebo-adjusted weight loss at 60 mg over 12 weeks with a clean neuropsychiatric safety profile, establishing peripheral CB1 inverse agonism as a mechanistically distinct, non-incretin obesity pathway. The mechanism operates through leptin-resistance reversal and direct adipose and hepatic lipid suppression, positioning it as a complement to GLP-1/GIP therapies.
Can TS-104, a First-in-Class Peptide-Drug Conjugate, Achieve a Tolerable Dose-Escalation Profile in Solid Tumors Without Dose-Limiting Toxicity in 2026?
TS-104 is a first-in-class, fully synthetic peptide-drug conjugate that couples a polyspecific integrin-binding peptide (PIP) to the cytotoxin MMAE. Whether it achieves a tolerable dose-escalation profile without dose-limiting toxicity in humans remains open: FDA IND clearance was granted in September 2026, and the first-in-human Phase 1 trial (NCT07814248) is now enrolling patients with advanced solid tumors.
What Does 2026 Research Reveal About Semaglutide's Neuroprotective Potential, and Why Did the EVOKE Trials Fail to Confirm It?
A 2026 review in Frontiers in Aging Neuroscience (Alhowail) concludes that semaglutide's neuroprotective mechanisms — GLP-1 receptor activation in the brain, reduced neuroinflammation, improved cerebral glucose metabolism, and attenuation of amyloid-β and tau pathology — are well-supported preclinically. The EVOKE and EVOKE+ Phase 3 trials found no cognitive benefit in established Alzheimer's disease, shifting the hypothesis toward early prevention.
How Does Mazdutide's Dose-Response Relationship in the 2026 U.S. Phase 2 Trial Inform Phase 3 Dose Selection for Obesity?
The 2026 United States phase 2 mazdutide trial produced placebo-corrected weight reductions of 6%, 14%, and 17% at week 32 across 3–6 mg, 10 mg, and 16 mg arms. The dose-response curve was monotonic but non-linear. The 10 mg arm captured most of the efficacy gain with tolerability burden comparable to approved agents, making it the leading phase 3 candidate.
What Did the First U.S. Phase 2 Mazdutide Trial Show for Weight Loss, HbA1c, and Tolerability in 2026?
The first United States phase 2 trial of mazdutide reported dose-dependent weight reductions of up to 18% at 32 weeks in adults with obesity or overweight. Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist. All active doses produced significant HbA1c decreases versus placebo. Gastrointestinal adverse events were the dominant tolerability signal with discontinuation rates reaching 20% at 16 mg.
Does Retatrutide Improve Liver Disease Outcomes Beyond Weight Loss in 2026 Preclinical and Translational Evidence?
Preclinical and translational data through 2026 indicate that retatrutide reduces hepatic steatosis and inflammation through mechanisms extending beyond caloric-deficit-driven weight loss. Glucagon receptor co-agonism drives direct hepatic fatty acid oxidation and suppresses de novo lipogenesis, while GLP-1 receptor activity attenuates hepatic inflammation via NF-κB inhibition. Whether these weight-independent pathways translate to durable fibrosis regression in humans remains an open question.
How Does Semaglutide Engage Hypothalamic Hunger Circuitry in Humans, and What Does the 2026 AgRP Neuron Evidence Mean for Dosing and Response Prediction?
Semaglutide suppresses appetite primarily by activating GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, but a 2026 Yale/PNAS study overturned the prevailing model: rather than silencing hunger-promoting AgRP neurons, semaglutide recruits them as required effectors of sustained weight loss. This reframing has direct implications for dose-escalation strategy and for predicting which patients will respond.
Which of the Seven Peptides Reviewed by the FDA's July 2026 Advisory Panel Have Sufficient Human Safety and Efficacy Data to Justify Compounding?
Of the seven peptides evaluated by the FDA's Compounding Advisory Committee in July 2026, only Semax carries a meaningful human clinical dataset — a Russian regulatory approval backed by published controlled trials. MOTS-c and Epitalon have limited observational human data. BPC-157, TB-500, KPV, and Emideltide lack adequate human safety or efficacy evidence by the FDA's 503A evidentiary standard.
Does the 2026 BPC-157 Hamstring Strain RCT (NCT07437547) Use MRI Injury Volume and Return-to-Sport as Co-Primary Endpoints?
Yes. NCT07437547, a Phase 2 randomised, double-blind, placebo-controlled trial currently recruiting in 2026, designates two co-primary endpoints: time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14. The trial enrols 120 adults with MRI-confirmed acute grade II hamstring strain and administers subcutaneous BPC-157 or placebo once daily for 14 days alongside a standardised rehabilitation programme.